Isis Pharmaceuticals Inc. initiated a six-month global phase III study of ISIS-APOCIIIRx, a triglyceride-lowering drug it plans to submit for FDA review in 2016. About 50 patients with the rare genetic condition familial chylomicronemia syndrome (FCS) will participate in the trial, which will measure as its primary endpoint percent change in fasting triglycerides from baseline at 13 weeks.